JP2015518896A - 新規イミノ糖およびそれらの用途 - Google Patents

新規イミノ糖およびそれらの用途 Download PDF

Info

Publication number
JP2015518896A
JP2015518896A JP2015516166A JP2015516166A JP2015518896A JP 2015518896 A JP2015518896 A JP 2015518896A JP 2015516166 A JP2015516166 A JP 2015516166A JP 2015516166 A JP2015516166 A JP 2015516166A JP 2015518896 A JP2015518896 A JP 2015518896A
Authority
JP
Japan
Prior art keywords
alkyl
compound
group
formula
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015516166A
Other languages
English (en)
Japanese (ja)
Inventor
キアペス，ジェー．エル．
レイン，ピーター
ドウェック，レイモンド
ジッツマン，ニコル
ポロック，ステファニー
Original Assignee
ユニザー ヴィロロジー，エルエルシー
ユニザー ヴィロロジー，エルエルシー
ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード
ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニザー ヴィロロジー，エルエルシー, ユニザー ヴィロロジー，エルエルシー, ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード, ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード filed Critical ユニザー ヴィロロジー，エルエルシー
Publication of JP2015518896A publication Critical patent/JP2015518896A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2015516166A 2012-06-06 2013-06-05 新規イミノ糖およびそれらの用途 Pending JP2015518896A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656265P 2012-06-06 2012-06-06
US61/656,265 2012-06-06
PCT/US2013/044285 WO2013184780A1 (en) 2012-06-06 2013-06-05 Novel iminosugars and their applications

Publications (1)

Publication Number Publication Date
JP2015518896A true JP2015518896A (ja) 2015-07-06

Family

ID=49712581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516166A Pending JP2015518896A (ja) 2012-06-06 2013-06-05 新規イミノ糖およびそれらの用途

Country Status (8)

Country Link
US (1) US8921568B2 (https=)
EP (1) EP2858642A4 (https=)
JP (1) JP2015518896A (https=)
KR (1) KR20150035767A (https=)
CN (1) CN104703597A (https=)
CA (1) CA2875975A1 (https=)
IN (1) IN2014MN02539A (https=)
WO (1) WO2013184780A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113425720A (zh) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516577A (ja) * 1996-07-15 2000-12-12 ユニフェルシテイト ファン アムステルダム デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途
JP2003506406A (ja) * 1999-08-10 2003-02-18 ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード 長鎖ｎ−アルキル化合物およびそのオキサ誘導体
JP2003522791A (ja) * 2000-02-14 2003-07-29 ファルマシア コーポレイション 肝炎ウイルス感染症治療用ｎ‐置換‐１，５‐ジデオキシ‐１，５‐イミノ‐ｄ‐グルシトール化合物の使用
JP2007536240A (ja) * 2004-05-04 2007-12-13 アカデミア シニカ 抗コロナウイルス化合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6011902B2 (ja) * 1979-12-27 1985-03-28 日本新薬株式会社 モラノリンの誘導体
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
KR20010033028A (ko) 1997-12-11 2001-04-25 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 막-관련 바이러스 복제의 억제
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
DE69932154T2 (de) 1998-02-12 2007-05-31 G.D. Searle Llc, Chicago Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen
ATE402701T1 (de) 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
RU2263672C2 (ru) 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
CN1694696A (zh) 2002-09-23 2005-11-09 牛津大学校委会 亚氨基糖衍生物在抑制离子通道活性中的应用
WO2005033093A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
KR100611931B1 (ko) 2004-09-02 2006-08-11 강경태 광학활성 알콕시알콜 화합물, 이로부터 유도되는 광학활성1,3-페닐렌-비스[4-(4-알콕시)페닐이미노메틸]벤조에이트화합물 및 이들의 제조방법
BRPI0609614A2 (pt) 2005-04-04 2010-04-20 Univ Pontificia Catolica Chile uso de ezetimiba na prevenção e tratamento de litìases de colesterol na árvore biliar
CN104876855A (zh) 2006-05-24 2015-09-02 联合治疗公司 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
KR20100127842A (ko) 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
WO2010027996A1 (en) * 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
EP2400843B1 (en) 2009-02-24 2015-11-11 United Therapeutics Corporation Iminosugars and methods of treating arenaviral infections
US8703744B2 (en) 2009-03-27 2014-04-22 The Chancellor, Masters And Scholars Of The University Of Oxford Cholesterol level lowering liposomes
ES2524361T3 (es) 2009-06-12 2014-12-05 United Therapeutics Corporation Iminoazúcares para su uso en el tratamiento de enfermedades por bunyavirus y togavirus
CA2772807A1 (en) 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Methods of treating poxviral infections
JP5653438B2 (ja) 2009-09-04 2015-01-14 ユナイテッド セラピューティクス コーポレイション オルトミクソウイルス感染の治療方法
CA2772813A1 (en) 2009-09-04 2011-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Iminosugars and methods of treating filoviral diseases
US20110136868A1 (en) 2009-12-07 2011-06-09 University Of Oxford Agents for inhibiting osteoclastogenesis and/or osteoclast activation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000516577A (ja) * 1996-07-15 2000-12-12 ユニフェルシテイト ファン アムステルダム デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途
JP2010031062A (ja) * 1996-07-15 2010-02-12 Macrozyme Dnm Bv デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途
JP2003506406A (ja) * 1999-08-10 2003-02-18 ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード 長鎖ｎ−アルキル化合物およびそのオキサ誘導体
JP2003522791A (ja) * 2000-02-14 2003-07-29 ファルマシア コーポレイション 肝炎ウイルス感染症治療用ｎ‐置換‐１，５‐ジデオキシ‐１，５‐イミノ‐ｄ‐グルシトール化合物の使用
JP2007536240A (ja) * 2004-05-04 2007-12-13 アカデミア シニカ 抗コロナウイルス化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 12, no. 3, JPN6017004449, 2008, pages 414 - 423, ISSN: 0003498319 *
化学大辞典編集委員会編, 化学大辞典１ 縮刷版, vol. 縮刷版第３２刷, JPN6017004453, 1989, pages 377 - 390, ISSN: 0003498320 *

Also Published As

Publication number Publication date
US8921568B2 (en) 2014-12-30
IN2014MN02539A (https=) 2015-07-24
CN104703597A (zh) 2015-06-10
EP2858642A1 (en) 2015-04-15
WO2013184780A1 (en) 2013-12-12
CA2875975A1 (en) 2013-12-12
KR20150035767A (ko) 2015-04-07
US20130331578A1 (en) 2013-12-12
EP2858642A4 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
CA2902721C (en) Compounds and uses thereof for the modulation of hemoglobin
AU2014237340C1 (en) Compounds and uses thereof for the modulation of hemoglobin
JP2016164168A (ja) ホスホジエステラーゼ阻害剤としてのベンゾジオキソールまたはベンゾジオキセピンヘテロ環化合物
US20250248990A1 (en) Quinolines that modulate serca and their use for treating disease
KR0160112B1 (ko) 심장보호 작용을 갖는 토코페롤 유사체
ES3055898T3 (en) Alpha-truxillic acid derivatives and pharmaceutical compositions thereof
EP2032561A2 (fr) Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
US12133839B2 (en) Cannabinoid derivatives and methods for their preparation
US8921568B2 (en) Iminosugars and their applications
JP3072912B2 (ja) コレステロール低下トコフェロール類似体
EP3638222A1 (en) Enzyme-triggered carbon monoxide releasing molecules
EP4581012A2 (en) Novel ionizable lipids and lipid nanoparticles and methods of using the same
KR900006132B1 (ko) 젬-디할로-1,8-디아미노-4-아자-옥탄 및 이의 제조방법
ES2843511T3 (es) Métodos para reducir las concentraciones en sangre de triglicéridos, colesterol total y lipoproteínas de baja densidad
WO2005049619A1 (fr) Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques
JP2007537979A (ja) トコフェロールに加えて他の少なくとも１種の薬活性材料も含有する化学化合物
EP4037685B1 (en) Quinoline that modulate serca and its use for treating disease
FI87923C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-hydroxy-4-(substituerad alkenyl)cyklohexankarboxylsyror

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171024